Welcome to this section dedicated to the financial community and to our shareholders. Here we make available our financial information, AGM reports as well as documents which have been presented to the financial community.
Neovacs is a public French biotechnology company developing therapeutic vaccines for the treatment for chronic autoimmune and inflammatory diseases. Listed on NYSE Alternext in Paris since 2010, it also enjoys long-term support from key shareholders.
Neovacs’ therapeutic vaccines are developed in severe diseases with unmet medical needs. The target market for Kinoids is estimated at over $27 billion (source: pharmaceutical company data), with potential to reach still broader markets.
2015 Financial Calendar
- Full-Year results 2014 February 27, 2015
- Shareholders’ AGM April 8,2015
- Half-Year Results 2015 September 4, 2015